- Home
- PIM vs GALT Comparison
PIM vs GALT Comparison
Compare PIM & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | GALT |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 176.7M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | PIM | GALT |
|---|---|---|
| Price | $3.21 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 60.8K | ★ 248.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $64.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $1.15 |
| 52 Week High | $3.50 | $7.13 |
Technical Indicators
Market Signals| Indicator | PIM | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 49.49 |
| Support Level | N/A | $2.88 |
| Resistance Level | $3.37 | $3.27 |
| Average True Range (ATR) | 0.03 | 0.22 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 17.65 | 43.95 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.